Docket Number:12A-1050527
Inventor:Te-Chang Lee, Tsann-Long Su
IP Status:Pending
Abstract:
We have recently designed and synthesized a series of indolizino[6,7-b]indole derivatives, which were designed as hybrid molecules of b-carboline (topoisomerase I and II inhibitory moiety) and bis(hydroxymethyl)pyrrole (DNA cross-linking moiety). We demonstrated that these hybrid molecules exhibited potent antitumor activity both in vitro and in tumor xenograft models. Interestingly, we found that these derivatives possess multi-mode of action, such as inhibition of topo I and topo II and induction of DNA cross-linking. Of these derivatives, we found that compound BO-1978 alone or in combination with other chemotherapeutic agents exhibited significant suppression of the growth of various human non-small cell lung cancer (NSCLC) in xenograft and orthotopic models. More recently, we further demonstrated that BO-1978 effectively suppressed various small cell lung cancer (SCLC, H526及 H211) cells both in vitro and in animal models. Long term survival (>430 days) or complete remission of xenograft tumor in nude mice induced by BO-1978 alone or in combination of BO-1978 and irinotecan, respectively, was observed. The current patent application discloses the use of BO-1978 alone or in combination with other anticancer agents for the treatment SCLC.
Fields of Application:
Treatment of small cell lung cancers (SCLC)
Advantages when compared to the existing technologies:
BO-1978 is more potent than cisplatin, etoposide and irinotecan, which are currently used for the treatment of small-cell lung cancer (SCLC) patient, against various SCLC in xenograft models. Our current studies also demonstrate that BO-1978 alone or in combination with other anticancer drugs significantly suppressed SCLC cells in animal models; Long term survival (>430 days) or complete remission of xenograft tumor in nude mice induced by BO-1978 alone or in combination of BO-1978 and irinotecan, respectively, was observed. BO-1978 exhibits multi-mode of mechanism actions, low toxicity with high bioavailability in animals. All these together, it indicates that there is high potential to develop BO-1978 as a clinical use drug for the treatment of SCLC.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
